MARKET

INFI

INFI

Infinity Pharmaceuticals Inc
NASDAQ
0.5411
-0.0139
-2.50%
Closed 14:39 11/25 EST
OPEN
0.5500
PREV CLOSE
0.5550
HIGH
0.5645
LOW
0.5300
VOLUME
339.31K
TURNOVER
0
52 WEEK HIGH
2.810
52 WEEK LOW
0.4605
MARKET CAP
48.34M
P/E (TTM)
-1.0315
1D
5D
1M
3M
1Y
5Y
Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass., November 22, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, to...
Business Wire · 6d ago
Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the ...
Zacks · 11/17 14:35
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
Benzinga · 11/16 15:06
B. Riley Securities Downgrades Infinity Pharmaceuticals to Neutral, Lowers Price Target to $1.5
Benzinga · 11/16 13:02
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/15 10:19
--B. Riley Downgrades Infinity Pharmaceuticals to Neutral From Buy, Lowers PT to $1.50 From $3; Moves to Sidelines Until Partner Helps Advance Eganelisib
--B. Riley Downgrades Infinity Pharmaceuticals to Neutral From Buy, Lowers PT to $1.50 From $3; Moves to Sidelines Until Partner Helps Advance Eganelisib
MT Newswires · 11/15 07:59
Infinity Pharma falls 24% on Q3 revenue miss
Seekingalpha · 11/14 18:31
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Benzinga · 11/14 18:05
More
About INFI
Infinity Pharmaceuticals, Inc. clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase 1/1b clinical study.

Webull offers kinds of Infinity Pharmaceuticals Inc. stock information, including NASDAQ:INFI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INFI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INFI stock methods without spending real money on the virtual paper trading platform.